TN2012000157A1 - Treatment using reprogrammed mature adult cells - Google Patents
Treatment using reprogrammed mature adult cellsInfo
- Publication number
- TN2012000157A1 TN2012000157A1 TNP2012000157A TN2012000157A TN2012000157A1 TN 2012000157 A1 TN2012000157 A1 TN 2012000157A1 TN P2012000157 A TNP2012000157 A TN P2012000157A TN 2012000157 A TN2012000157 A TN 2012000157A TN 2012000157 A1 TN2012000157 A1 TN 2012000157A1
- Authority
- TN
- Tunisia
- Prior art keywords
- cells
- patient
- retrodifferentiated
- transdifferentiated
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
Abstract
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2009/051396 WO2011048350A1 (en) | 2009-10-19 | 2009-10-19 | Treatment using reprogrammed mature adult cells |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2012000157A1 true TN2012000157A1 (en) | 2013-12-12 |
Family
ID=42199514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2012000157A TN2012000157A1 (en) | 2009-10-19 | 2012-04-04 | Treatment using reprogrammed mature adult cells |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2490702A1 (en) |
JP (1) | JP6073135B2 (en) |
KR (1) | KR101766203B1 (en) |
CN (1) | CN102647989A (en) |
AU (1) | AU2009354350B2 (en) |
CA (1) | CA2781522A1 (en) |
CH (1) | CH704227B1 (en) |
CU (1) | CU24006B1 (en) |
IL (1) | IL218902A (en) |
MA (1) | MA33740B1 (en) |
MX (1) | MX2012004522A (en) |
RU (1) | RU2635317C2 (en) |
TN (1) | TN2012000157A1 (en) |
UA (1) | UA109265C2 (en) |
WO (1) | WO2011048350A1 (en) |
ZA (1) | ZA201202664B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107075470A (en) | 2014-09-18 | 2017-08-18 | 北卡罗来纳大学 | Mammal lung spheroid and lung sphere cells and its application |
JP6113133B2 (en) | 2014-11-06 | 2017-04-12 | 日本メナード化粧品株式会社 | Stem cell undifferentiated state maintenance agent and growth promoter |
CA3001859A1 (en) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
CN107114355A (en) * | 2016-08-01 | 2017-09-01 | 北京世纪劲得生物技术有限公司 | A kind of fat cell protection liquid and preparation method thereof |
MX2019010196A (en) * | 2017-02-28 | 2019-12-19 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins. |
CN109731012A (en) * | 2017-10-30 | 2019-05-10 | 邹兆中 | It improves biological immune and treats the active method of active principle |
CN109706119B (en) * | 2018-04-13 | 2020-11-27 | 诺未科技(北京)有限公司 | Culture system and method for expanding hematopoietic stem cells and application thereof |
CN113423725A (en) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | Genetically engineered hematopoietic stem cells and uses thereof |
KR20200025210A (en) * | 2018-08-29 | 2020-03-10 | 주식회사 스템모어 | Composition for culturing dermal papilla cells and the method for culturing dermal papilla cells using the same |
WO2021240204A1 (en) * | 2020-05-23 | 2021-12-02 | Pakravan Nafiseh | Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy |
CN114231481B (en) * | 2021-12-21 | 2023-07-18 | 中国人民解放军总医院 | Chemical induction method for taking reprogramming Cheng Zhenpi fibroblast as endothelial progenitor cell |
CN117025504A (en) * | 2022-05-10 | 2023-11-10 | 上海赛立维生物科技有限公司 | Preparation method and application of gall bladder precursor-like cells |
WO2024050517A1 (en) * | 2022-09-02 | 2024-03-07 | The University Of North Carolina At Chapel Hill | Methods of making and using anticancer reprogrammed b cells |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
GB9502022D0 (en) * | 1995-02-02 | 1995-03-22 | Abuljadayel Ilham M S | A method for preparing lymphohaematopoietic progenitor cells |
US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
US7112440B2 (en) * | 1995-02-02 | 2006-09-26 | Ghazi Jaswinder Dhoot | Method of increasing the relative number of CD45 low cells in a cell population |
WO1996035224A1 (en) * | 1995-05-02 | 1996-11-07 | Philips Electronics N.V. | Colour cathode ray tube |
US20050037490A1 (en) * | 1999-10-29 | 2005-02-17 | Lawrence Rosenberg | Medium for preparing dedifferentiated cells |
TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
WO2006014642A1 (en) * | 2004-07-22 | 2006-02-09 | Five Prime Therapeutics, Inc. | Method of producing autologous embryonic stem cells |
WO2010115052A2 (en) * | 2009-04-03 | 2010-10-07 | The Mclean Hospital Corporation | Induced pluripotent stem cells |
-
2009
- 2009-10-19 RU RU2012120713A patent/RU2635317C2/en not_active IP Right Cessation
- 2009-10-19 WO PCT/GB2009/051396 patent/WO2011048350A1/en active Application Filing
- 2009-10-19 KR KR1020127012911A patent/KR101766203B1/en active IP Right Grant
- 2009-10-19 JP JP2012534757A patent/JP6073135B2/en not_active Expired - Fee Related
- 2009-10-19 UA UAA201205968A patent/UA109265C2/en unknown
- 2009-10-19 MX MX2012004522A patent/MX2012004522A/en unknown
- 2009-10-19 CH CH00524/12A patent/CH704227B1/en not_active IP Right Cessation
- 2009-10-19 CA CA2781522A patent/CA2781522A1/en not_active Abandoned
- 2009-10-19 AU AU2009354350A patent/AU2009354350B2/en not_active Ceased
- 2009-10-19 CN CN2009801630439A patent/CN102647989A/en active Pending
- 2009-10-19 EP EP09736651A patent/EP2490702A1/en not_active Withdrawn
-
2012
- 2012-03-28 IL IL218902A patent/IL218902A/en not_active IP Right Cessation
- 2012-04-04 TN TNP2012000157A patent/TN2012000157A1/en unknown
- 2012-04-12 ZA ZA2012/02664A patent/ZA201202664B/en unknown
- 2012-04-19 CU CU2012000063A patent/CU24006B1/en active IP Right Grant
- 2012-05-11 MA MA34857A patent/MA33740B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CU24006B1 (en) | 2014-06-27 |
RU2012120713A (en) | 2013-11-27 |
RU2635317C2 (en) | 2017-11-10 |
AU2009354350B2 (en) | 2015-09-03 |
JP2013508343A (en) | 2013-03-07 |
WO2011048350A1 (en) | 2011-04-28 |
MX2012004522A (en) | 2012-05-08 |
AU2009354350A1 (en) | 2012-04-19 |
MA33740B1 (en) | 2012-11-01 |
EP2490702A1 (en) | 2012-08-29 |
ZA201202664B (en) | 2013-02-27 |
IL218902A0 (en) | 2012-06-28 |
UA109265C2 (en) | 2015-08-10 |
CU20120063A7 (en) | 2012-10-15 |
KR20120099686A (en) | 2012-09-11 |
CH704227B1 (en) | 2015-05-15 |
JP6073135B2 (en) | 2017-02-01 |
KR101766203B1 (en) | 2017-08-08 |
IL218902A (en) | 2017-06-29 |
CA2781522A1 (en) | 2011-04-28 |
CN102647989A (en) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2012000157A1 (en) | Treatment using reprogrammed mature adult cells | |
IL260117A (en) | Treatment of diseases, disorders or conditions of the lung using placental cells | |
MX2019005130A (en) | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin. | |
TR201911199T4 (en) | Treatment to increase cell growth. | |
WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
MX2011009751A (en) | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. | |
WO2007131232A3 (en) | Compositions and their uses directed to ptpr alpha | |
EP2365816A4 (en) | Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases | |
WO2011079261A3 (en) | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf | |
MX2013002381A (en) | Bone marrow derived cd271 precursor cells for cardiac repair. | |
NZ607195A (en) | Methods for treating and/or reversing neurodegenerative diseases and/or disorders | |
WO2013078376A3 (en) | Isoxazole treatments for diabetes | |
MY157168A (en) | Treatment using reprogrammed mature adult cells | |
MX356814B (en) | Methods and compositions for neuroprotection. | |
WO2013033165A3 (en) | Compositions, kits and methods for treating obesity, diabetes and hyperglycemia | |
PL2470213T3 (en) | Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast | |
WO2012177565A3 (en) | Regulation of macrophage activation using mir - 125b | |
AR073910A1 (en) | TREATMENT OF DIFFERENT DISEASES, USING REPROGRAMED MATURE ADULT CELLS. | |
EP2049656A4 (en) | Use of late passage mesenchymal stem cells (mscs) for treatment of cardiac rhythm disorders | |
UY32186A (en) | TREATMENT USING REPROGRAMED MATURE ADULT CELLS | |
TR201204532T1 (en) | Treatment using re-programmed mature adult cells. | |
WO2010110602A3 (en) | Method for regenerating dopaminergic neurons in the substantia nigra pars compacta using human adult stem cells or precursor cells | |
TH125509A (en) | Treatment that uses reprogrammed mature adult cells | |
TH125509B (en) | Treatment using reprogrammed mature adult cells | |
UA49781U (en) | METHOD FOR treatment of bronchial asthma at children in acute period |